Judge extends TRO against Amphastar through 10/28/11; MNTA drops infringement claims on ‘886 patent; updated list of patent claims asserted by MNTA against Amphastar; musings on the Bolar exemption; musings on the timing of a possible MNTA-Amphastar settlement; 2011-2013 news flow; miscellaneous updates on MNTA’s IP patent estate; more Aubagio data from TESMO trial; more Lemtrada data from CARE-MS I trial; BIIB/ABT present phase-2b Daclizumab data; JNJ plans Xarelto sNDA submission for ACS by end of 2011; new version of “How will Xarelto/Eliquis/Pradaxa affect US Lovenox sales?”; new version of “What’s New in the Anticoagulant Arena?”
Why do you say he has destroyed lives, everyone makes their own decisions.
I am puzzled as to how to proceed with MNTA but the sky is not falling either.
Copaxene is why most of us are here, that is what we are waiting for. That is the game changer not MNTA's current generic. All that happened today is no suprise, it was just a matter of when it would happen.